Overview

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Status:
Not yet recruiting
Trial end date:
2023-09-16
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.
Phase:
Phase 3
Details
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.